Shattuck Labs CFO Increases Stake; Warrants Tied to SL-325 Trial Data
Rhea-AI Filing Summary
Shattuck Labs CFO Andrew R. Neill purchased 64,027 shares and received 64,027 accompanying warrants in a private placement that closed on August 25, 2025. The combined price paid for each share plus warrant was $0.8677, and the warrants have an exercise price of $1.0846. After the transaction the reporting person beneficially owned 237,473 shares. The warrants are exercisable any time after issuance until 30 days following public disclosure of specified Phase 1 clinical trial data and the planned Phase 2 design for SL-325.
Positive
- Material insider participation: CFO purchased 64,027 shares and accompanying warrants, increasing his beneficial ownership to 237,473 shares
- Aligned incentives: Warrants exercisable contingent on public disclosure of Phase 1 data and Phase 2 design for SL-325, linking upside to clinical progress
- Transparent disclosure: Form 4 clearly reports transaction details including price and warrant terms
Negative
- Conditional exercisability: Warrants cannot be exercised until the issuer publicly announces specified clinical data and Phase 2 design, delaying potential value realization
- Private placement price: Purchase price of $0.8677 per share-plus-warrant may imply dilution risk for existing shareholders if exercised
Insights
TL;DR: Insider purchase increases CFO stake; transaction size is modest but aligns financial interest with company outcomes.
The reported private placement shows the CFO acquired 64,027 shares plus 64,027 detachable warrants at $0.8677 per share-plus-warrant, raising his beneficial ownership to 237,473 shares. For a public market observer, this is a routine insider buy rather than a material corporate event. The warrants' exercisability depends on the company publicly releasing Phase 1 clinical data and a Phase 2 design, linking value realization to clinical milestones for SL-325.
TL;DR: Transaction is a standard, disclosed insider participation in a private placement with conditional warrant terms tied to clinical disclosures.
The Form 4 transparently discloses the CFO's participation in the issuer's August 25, 2025 private placement and the contingent exercise window for warrants. From a governance perspective, the filing meets Section 16 reporting requirements and specifies the condition triggering warrant exercisability, which is relevant for assessing alignment of executive incentives with milestone-driven value creation.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Warrants (Right to Buy) | 64,027 | $0.00 | -- |
| Grant/Award | Common Stock | 64,027 | $0.8677 | $56K |
Footnotes (1)
- On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.
